Diligence memo · auto-generated · as of July 2, 2026
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Relay Therapeutics, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Relay Therapeutics, Inc. has raised $30M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2024-01-10.
Most recent recorded round closed around 2024-01-10.
Valuation (modeled)modeled
Provath models Relay Therapeutics, Inc. at approximately $253M (range $63M–$496M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.95× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.5 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.